CIBMTR Analysis Confirms Ongoing Role for Autologous Transplant in Chemosensitive Relapsed DLBCL

Oncologist. 2020 Jul;25 Suppl 1(Suppl 1):S10-S11. doi: 10.1634/theoncologist.2020-0554. Epub 2020 Jun 26.

Abstract

In the era of chimeric antigen receptor (CAR) T‐cell therapy for relapsed/refractory diffuse large B‐cell lymphoma (DLBCL), a new analysis from the Center for International Blood & Marrow Transplant Research (CIBMTR) confirms an ongoing role for autologous transplant in patients with chemosensitive relapsed DLBCL.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Autografts
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Longitudinal Studies
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Neoplasm Recurrence, Local
  • Transplantation, Autologous
  • Treatment Outcome